UroGen Pharma (URGN) EBIAT (2017 - 2025)
UroGen Pharma (URGN) has disclosed EBIAT for 9 consecutive years, with -$26.4 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, EBIAT rose 29.72% year-over-year to -$26.4 million, compared with a TTM value of -$153.5 million through Dec 2025, down 20.98%, and an annual FY2025 reading of -$153.5 million, down 20.98% over the prior year.
- EBIAT was -$26.4 million for Q4 2025 at UroGen Pharma, up from -$33.3 million in the prior quarter.
- Across five years, EBIAT topped out at -$21.9 million in Q3 2023 and bottomed at -$49.9 million in Q2 2025.
- Average EBIAT over 5 years is -$30.2 million, with a median of -$28.4 million recorded in 2021.
- The sharpest move saw EBIAT surged 31.38% in 2021, then tumbled 49.51% in 2025.
- Year by year, EBIAT stood at -$28.5 million in 2021, then dropped by 1.47% to -$28.9 million in 2022, then increased by 9.88% to -$26.0 million in 2023, then tumbled by 44.19% to -$37.5 million in 2024, then grew by 29.72% to -$26.4 million in 2025.
- Business Quant data shows EBIAT for URGN at -$26.4 million in Q4 2025, -$33.3 million in Q3 2025, and -$49.9 million in Q2 2025.